A new inhaler called Airsupra, which combines a bronchodilator and an anti-inflammatory steroid, has been shown to significantly reduce severe asthma attacks and steroid use compared to albuterol alone, potentially changing how mild asthma is treated by addressing both symptoms and underlying inflammation simultaneously.
Flovent, a widely used asthma inhaler, is being discontinued by GSK in favor of an authorized generic version. This change has raised concerns among doctors and patients about insurance coverage and potential cost increases, despite the generic's lower cash price. Patients are advised to consult with their doctors and insurance companies to ensure continuity of care and to explore other medication options if necessary.
A new study led by Boston scientists suggests that delivering COVID-19 vaccines directly to the lungs using a device similar to an asthma inhaler can significantly improve immunity and protection in the respiratory system, potentially blocking infections more effectively. The research demonstrates that vaccines delivered to the lungs generate a larger army of immune cells in the breathing passages, intercepting and killing virus particles before they cause illness. This approach, along with nasal sprays, shows promise in boosting immune responses in the nose and lungs, where it matters most in preventing infection. However, further research and testing are needed to ensure safety and develop stable formulations for existing mRNA vaccines.